San Diego-dependent Viking Therapeutics marked by itself as a serious competitor within the weight loss drug current market in February soon after revealing promising facts from the mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when provided as being a weekly injection As well as i